Tags |
|
|
Links |
|
|
Digg It - The Measurement of Manager Training
THE MEASUREMENT OF TRAINING: Evaluation is one of the most valuable
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
— and challenging — aspects of a training manager’s job. A well-pl
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
nned and on-target evaluation process can be the tool which separat
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
s a superlative training department from a merely satisfactory one.
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
Evaluation can help you determine whether what you are offering is
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
successfully meeting existing corporate needs.
It can help you to
It can help you to
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
dentify needs which have previously not been expressed, and tap a s
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
urce of new training opportunities.
Unfortunately, it is not enoug
Unfortunately, it is not enoug
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
to ask the question “Did it work?”. Not only will the answer vary
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
according to the way the evaluation process is conducted, but succe
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
s is always relative to each organization’s individual goals.
As K
As K
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
en Wessel, an independent training consultant in the Chicago area,
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
uts it: “Nothing will fill the bill in all instances. Evaluation ha
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
to be tailor-made for organizational objectives.”
In search of so
In search of so
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
e hands on tips to help you make the evaluation process — and its o
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
tcome — smoother and more effective, we interviewed nine training m
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
nagers and three consultants in different industries, different-siz
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
d firms, and different locations. All twelve of them made it clear
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
hat the questioning process itself is crucial, and that this proces
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
really begins at the initiation of the training cycle, not the end
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/24043/diggit-The-Measurement-of-Manager-Training.html">The Measurement of Manager Training</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/24043/diggit-The-Measurement-of-Manager-Training.html]The Measurement of Manager Training[/url]
Related Articles:
Preparation of the Marketing Campaign: Advertising
Ditch Your Corporate Cubicle And Join The Ranks Of Web Workers Making Money Online
Tips for Organizational Stress Management
Bookmark it:
|